Abstract
To date the locus with the most robust human genetic association to COVID-19 susceptibility is 3p21.31. Here, we integrate genome-scale CRISPR loss-of-function screens and eQTLs in diverse cell types and tissues to pinpoint genes underlying COVID-19 risk. Our findings identify SLC6A20 and CXCR6 as putative causal genes that mediate COVID-19 risk and highlight the usefulness of this integrative approach to bridge the divide between correlational and causal studies of human biology.
Competing Interest Statement
N.E.S. is an advisor to Vertex. T.L. advises and has equity in Variant Bio, and is a member of the scientific advisory board of Goldfinch Bio. The remaining authors declare that they have no competing interests.
Funding Statement
S.K. and T.L. are supported by NIH/NHLBI (R01HL142028). Z.D. is supported by an American Heart Association postdoctoral fellowship (grant no. 20POST35220040). Postdoctoral fellowship support for T.X.J. is provided by the NIH (grant no. R01AI123155). B.R.t. is supported by the Marc Haas Foundation, the National Institutes of Health, and DARPA's PREPARE Program (HR0011-20-2-0040). N.E.S. is supported by NYU and NYGC startup funds, NIH/NHGRI (DP2HG010099), NIH/NCI (R01CA218668), DARPA (D18AP00053), the Sidney Kimmel Foundation, and the Brain and Behavior Foundation. T.L. is supported by NIH/NIMH (R01MH106842) and NIH/NHGRI (UM1HG008901).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Not applicable - we are analyzing already published data
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The datasets analyzed during the current study are available from the following repositories: CRISPR screen data can be accessed from GEO repository under an accession number GSE158298, summary statistics of the COVID-19 GWAS (release 3) from the COVID-19 Human Genetics Initiative webpage, eQTL summary statistics can be downloaded from the eQTL Catalogue and the GTEx Portal.
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE158298